No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

Andrea L. Cathcart, Henry Lik‐Yuen Chan, Neeru Bhardwaj, Yang Liu, Patrick Marcellin, Calvin Q. Pan, S. Shalimar, Stephanie Cox, Bandita Parhy, Eric S. Zhou,

Antimicrobial Agents and Chemotherapy · 2018 · 60 citations · 38 references

DOIFull text

Open access

Concepts

Abstract

After 96 weeks, the proportion of patients achieving virus suppression (HBV DNA < 69 IU/ml) was similar across treatment groups, and no substitutions associated with resistance to TAF or TDF were detected. (These studies have been registered at ClinicalTrials.gov under identifiers NCT01940471 and NCT01940341.).

References

38